Keyword Analysis & Research: encorafenib
Keyword Research: People who searched encorafenib also searched
Search Results related to encorafenib on Search Engine
-
Encorafenib Uses, Side Effects & Warnings - Drugs.com
https://www.drugs.com/mtm/encorafenib.html
WEBApr 26, 2023 · What is encorafenib? Encorafenib is used in combination with a medicine called binimetinib ( Mektovi) to treat melanoma ( skin cancer) that cannot be treated with surgery or has spread to other parts of the body.
DA: 73 PA: 14 MOZ Rank: 21
-
Encorafenib - Wikipedia
https://en.wikipedia.org/wiki/Encorafenib
WEBEncorafenib, sold under the brand name Braftovi, is a medication for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.
DA: 94 PA: 45 MOZ Rank: 31
-
Encorafenib: Uses, Interactions, Mechanism of Action - DrugBank …
https://go.drugbank.com/drugs/DB11718
WEBEncorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays with IC50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, such as BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth.
DA: 24 PA: 33 MOZ Rank: 68
-
Encorafenib: Cancer Treatment Uses, Side Effects, Dosage
https://www.medicinenet.com/encorafenib/article.htm
WEBNov 16, 2023 · Encorafenib is an anticancer (antineoplastic) medication used to treat metastatic melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC) in combination with either binimetinib or cetuximab. Side effects of encorafenib vary, depending on which drug it is used in combination with for cancer treatment.
DA: 12 PA: 25 MOZ Rank: 33
-
FDA Approves Encorafenib for Colorectal Cancer - NCI
https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-encorafenib-cetuximab-metastatic-colorectal
WEBMay 8, 2020 · The Food and Drug Administration (FDA) has approved encorafenib (Braftovi) for the treatment of some patients with colorectal cancer. The approval covers using encorafenib in combination with cetuximab (Erbitux) in adults with metastatic colorectal cancer whose tumors have a mutation in the BRAF gene, called V600E.
DA: 41 PA: 68 MOZ Rank: 100
-
Encorafenib (Oral Route) Description and Brand Names - Mayo Clinic
https://www.mayoclinic.org/drugs-supplements/encorafenib-oral-route/description/drg-20443856
WEBMar 1, 2024 · Encorafenib is used in combination with binimetinib to treat melanoma (skin cancer) that has spread or cannot be removed by surgery. It is only used if the melanoma cells have the BRAF V600E or V600K mutations. Your doctor will …
DA: 78 PA: 45 MOZ Rank: 75
-
Encorafenib - NCI - National Cancer Institute
https://www.cancer.gov/about-cancer/treatment/drugs/encorafenib
WEBEncorafenib is approved to be used with other drugs to treat patients whose cancer has a certain mutation in the BRAF gene, including: Colorectal cancer that has spread to other parts of the body. It is used with cetuximab in adults who …
DA: 67 PA: 57 MOZ Rank: 1
-
Encorafenib Oral: Uses, Side Effects, Interactions, Pictures ... - WebMD
https://www.webmd.com/drugs/2/drug-175523/encorafenib-oral/details
WEBEncorafenib is used to treat certain types of cancer (such as lung cancer, melanoma skin cancer, cancer in the colon or rectum). Encorafenib belongs to a class of drugs known as kinase...
DA: 55 PA: 79 MOZ Rank: 14
-
Encorafenib: MedlinePlus Drug Information
https://medlineplus.gov/druginfo/meds/a618040.html
WEBEncorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. How should this medicine be used? Encorafenib comes as a capsule to take by mouth.
DA: 81 PA: 98 MOZ Rank: 66
-
Celebrating a breakthrough: FDA endorses encorafenib plus …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11020023/
WEBJan 11, 2024 · Encorafenib is a second-generation oral rapidly accelerated fibrosarcoma (RAF) kinase inhibitor with enhanced properties, such as high bioavailability and the ability to maintain prolonged inhibition of mutant BRAFV600E due to its extended dissociation half-life (>30 h), setting it apart from other BRAF inhibitors such as dabrafenib that ...
DA: 32 PA: 89 MOZ Rank: 78